SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes: Boston Wednesday, August 6, 2025, 13:00 Hrs [IST] SOPHiA GENETICS, a clo ...

Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer, sending the biotech firm's shares surging more than twofold in premarket ...

The intervention involves the use of LYNPARZA tablets, available in 100mg and 150mg doses, aimed at treating high-risk breast cancer patients in the adjuvant setting. The primary goal is to monitor ...

Antibody-drug conjugates are currently being investigated in more than 260 clinical trials.“It’s going to be the next novel ...

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer in a late-stage study, sending the biotech firm's shares surging to a record ...

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

In an earnings call on July 29th, in which the company reported a 13% increase in half-year profits, he said about Britain ...

Common respiratory infections like COVID and the flu could awaken dormant breast cancer cells in the lungs and lead to ...

CHICAGO — Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk of disease progression or death ...

CHICAGO (Reuters) -Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or ...

He was in part referring to AstraZeneca's promising data shared at the 2025 American Society of Clinical Oncology annual meeting in Chicago, where several other companies also delivered positive ...